These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20466624)

  • 21. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
    Chen DB; Wang Y; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
    [No Abstract]   [Full Text] [Related]  

  • 24. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
    Keilholz U; Szelényi H; Siehl J; Foss HD; Knauf W; Thiel E
    Leuk Lymphoma; 1999 Nov; 35(5-6):641-2. PubMed ID: 10609806
    [No Abstract]   [Full Text] [Related]  

  • 25. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
    Boye J; Elter T; Engert A
    Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of 2 patients treated with
    Golstein SC; Muylle K; Vercruyssen M; Spilleboudt C; de Wind A; Bron D
    Eur J Haematol; 2018 Sep; 101(3):415-417. PubMed ID: 29719928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment and immunotherapy of Hodgkin's lymphoma.
    Klimm B; Schnell R; Diehl V; Engert A
    Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
    Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
    J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nodular lymphocyte predominant Hodgkin's lymphoma.
    Siddiqui N; Al-Diab AI
    Saudi Med J; 2005 Feb; 26(2):241-5. PubMed ID: 15770298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged hypogammaglobulinemia after adjuvant rituximab for Hodgkin's lymphoma presenting with refractory urticaria.
    Wolverton W; McClenathan B
    Ann Allergy Asthma Immunol; 2012 Dec; 109(6):473-4. PubMed ID: 23176893
    [No Abstract]   [Full Text] [Related]  

  • 36. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.
    Karuturi M; Hosing C; Fanale M; Medeiros LJ; Alousi AM; de Lima MJ; Qazilbash MH; Kebriaei P; Younes A; Khouri I; Andersson BS; Champlin R; Anderlini P; Popat U
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):991-4. PubMed ID: 23507470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected].
    Kimby E
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):7-10. PubMed ID: 12040528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma.
    Farhan R; Alqarni NS; Algiraigri AH
    J Taibah Univ Med Sci; 2020 Dec; 15(6):554-556. PubMed ID: 33318747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
    Milojkovic D; Mijovic A; Taylor CG; Mufti GJ; Pagliuca A
    Br J Haematol; 2000 Sep; 110(4):1013-4. PubMed ID: 11054097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.